|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,367,652: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 8,367,652?
US Patent 8,367,652, filed on August 11, 2008, and granted on February 5, 2013, claims to a specific class of compounds and their therapeutic applications, primarily focusing on their use as kinase inhibitors. The patent's scope encompasses:
- Chemical compounds characterized by specific molecular structures.
- Methods of synthesizing these compounds.
- Therapeutic methods employing these compounds, notably in treating certain cancers.
- Pharmaceutical compositions containing these compounds.
The patent covers a chemical space concentrated on pyrazolopyrimidine derivatives, which inhibit specific protein kinases such as BRAF and MEK. It claims the compounds’ structure, their preparation, and their use in medical treatment.
Key structural features:
- A core pyrazolopyrimidine moiety.
- Substituents at certain positions conferring kinase inhibitory activity.
- Specific substituents claimed to enhance selectivity and potency.
What Are the Main Claims?
The patent contains 25 claims, with the following being central:
- Claim 1: A chemical compound with a core pyrazolopyrimidine structure, substituted as specified in the claim, exhibiting kinase inhibitory activity.
- Claims 2–10: Variations on chemical structure, defining particular substituents at key positions, such as halogens, alkyl groups, or aromatic groups.
- Claims 11–15: Methods for synthesizing the claimed compounds, outlining reaction steps and conditions.
- Claims 16–20: Pharmaceutical compositions comprising the compounds, formulated for therapeutic administration.
- Claims 21–25: Methods of treating diseases, such as melanoma or other cancers, using the compounds.
The claims are directed both to the compounds per se and to their uses, making the patent a composition-of-matter and method-of-use patent.
Claim Scope Analysis
- The claim set is broad within the chemical class, covering multiple substitution patterns.
- The therapeutic claims hinge on demonstrating efficacy as kinase inhibitors, primarily against targets involved in oncogenic pathways.
- Narrower dependent claims specify particular compounds and methods, providing fallback positions for patent enforcement.
Patent Landscape Overview
Related Patents and Patent Applications
The patent landscape includes numerous filings by different entities targeting similar kinase pathways. Notables include:
- US Patent 7,880,759 (filed by Array BioPharma): Also covers pyrazolopyrimidines targeting BRAF kinases.
- EP Patent 2,502,854: Similar compounds with focus on kinase inhibition.
- Multiple applications filed between 2007 and 2010 expanding on the chemical space disclosed in US 8,367,652.
Competitor Positions
Major pharmaceutical companies operating in kinase inhibitors are active in this landscape:
- Array BioPharma: Holds multiple patents related to BRAF and MEK inhibitors.
- Novartis: Held patents on similar compounds, including Vemurafenib.
- Pfizer: Developed compounds targeting similar kinase pathways.
Patent Citations and Family
- US 8,367,652 is cited by subsequent applications aimed at optimized derivatives and combination therapies.
- Its family includes related patents in Europe, Australia, and Canada, maintaining patent rights in key markets.
Patent Term and Status
- Priority date: August 2008.
- Expiry: Based on patent term calculations, approximately August 2028, assuming maintenance fees are paid.
- Currently enforceable; no reports of invalidation or expiry.
Strategic Considerations
- The scope provides a broad platform for further derivative compounds.
- The claims covering synthesis and use support both product development and patent enforcement.
- Compatibility with combination therapies could be a focus for extending patent life or expanding coverage.
Key Takeaways
- US 8,367,652 claims a specific chemical class of kinase inhibitors with applications in oncology.
- The claims are broad regarding chemical structure, enabling coverage of various derivatives.
- The patent landscape is dense, with multiple patents targeting similar kinase pathways, especially BRAF and MEK.
- The patent family extends protections into other jurisdictions, reinforcing market position.
- Enforcement and licensing strategies should consider the overlapping patents and competing portfolios.
FAQs
1. Does US Patent 8,367,652 cover all kinase inhibitors for cancer? No. It specifically covers pyrazolopyrimidine derivatives with certain substitution patterns, not all kinase inhibitors.
2. Can additional patents be filed around this patent? Yes. New derivatives or formulations that do not infringe on the claims can be patented.
3. How does this patent compare with Vemurafenib patents? The patent covers different chemical scaffolds; Vemurafenib patents focus on BRAF inhibitors with distinct structures.
4. Is this patent still enforceable? Yes, it remains active until approximately August 2028, assuming maintenance fees are paid.
5. Can this patent be challenged? Potentially, through validity challenges such as prior art or obviousness arguments, but no current legal challenges are public.
References
- U.S. Patent and Trademark Office. (2013). Patent number 8,367,652.
- NCBI PubChem. (n.d.). Compound data for pyrazolopyrimidines.
- World Intellectual Property Organization. Patent landscape reports on kinase inhibitors.
- European Patent Office. Patent family data.
- R&D pipelines of major pharmaceutical companies in kinase inhibitors.
More… ↓
⤷ Start Trial
|
